Annexon Q2 Earnings Call Highlights

•2mo ago

Annexon Q2 Earnings Call Highlights

Tap title to read story

0:00 / 0:36

Annexon (NASDAQ:ANNX) said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study's existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarter assessment of the 15-month endpoint while seeking to capture longer-term efficacy data for a potential product label.

President and Chief Executive Officer Doug Love said the company's two lead programs are approaching

Published 2026-08-12 14:57:03 UTC · Published by JQJO

Prepared by Mahnoor A. · AI assisted

More context

Timeline

On July 31, 2025 Phase 3 ARCHER II trial completed enrollment with 659 patients.
On June 30, 2026 Annexon ended second quarter with $199.3 million in cash.
On August 12, 2026 Annexon announced Q2 loss and expanded ARCHER II trial endpoints.
On August 12, 2026 Annexon secured up to $200 million Oxford credit facility.
On August 12, 2026 Stock fell 6.37% in premarket trading following earnings miss.
On August 12, 2026 21:50 PKT No newer material development located during final freshness search.
In Q4 2026 Annexon expects Phase 3 ARCHER II 15-month endpoint assessment.
In Q4 2026 Annexon plans U.S. BLA submission for lead candidate tanruprubart.
In Q1 2027 Annexon plans sub-study analysis following 15-month trial readout.
In Q3 2027 Annexon expects ARCHER II trial completion including 24-month analysis.

Why it matters

Biotech firm Annexon expanded clinical endpoints and extended operational runway. Successful late-stage trials could bring novel therapies to retinal markets. Biopharmaceutical investors, geographic atrophy patients, and Guillain-Barré syndrome medical specialists. Cross-reference SEC filings against clinical trial registries for verification.

Coverage notes

Left: Highlights potential patient benefits and regulatory safety mechanisms for clinical therapies. Center: Reports financial loss, EPS miss, cash balance, and clinical timelines. Right: Emphasizes market reaction, capital burn rate, and non-dilutive debt financing.